Cyclerion Therapeutics (CYCN) Income towards Parent Company (2018 - 2025)

Cyclerion Therapeutics' Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$1.0 million for Q3 2025.

• In Q3 2025, Income towards Parent Company changed N/A year-over-year to -$1.0 million; the TTM figure through Dec 2025 stood at -$4.1 million (changed N/A YoY), while the FY2023 annual figure was $7.3 million, up 128.38% from the prior year.
• Income towards Parent Company was -$1.0 million for Q3 2025 at Cyclerion Therapeutics, up from -$1.7 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $13.5 million in Q3 2023 to a low of -$16.2 million in Q2 2021.
• Historically, Income towards Parent Company has averaged -$6.2 million across 4 years, with a median of -$4.9 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Income towards Parent Company increased 3.07% in 2022, then jumped 321.28% in 2023.
• A 4-year view of Income towards Parent Company shows it stood at -$14.3 million in 2021, then soared by 79.82% to -$2.9 million in 2022, then surged by 565.74% to $13.5 million in 2023, then slumped by 107.47% to -$1.0 million in 2025.
• The last three Income towards Parent Company figures came in at -$1.0 million (Q3 2025), -$1.7 million (Q2 2025), and -$1.5 million (Q1 2025), per Business Quant data.